JP2002503333A - 自動分析実施方法および装置 - Google Patents
自動分析実施方法および装置Info
- Publication number
- JP2002503333A JP2002503333A JP50604198A JP50604198A JP2002503333A JP 2002503333 A JP2002503333 A JP 2002503333A JP 50604198 A JP50604198 A JP 50604198A JP 50604198 A JP50604198 A JP 50604198A JP 2002503333 A JP2002503333 A JP 2002503333A
- Authority
- JP
- Japan
- Prior art keywords
- whole blood
- sample
- blood sample
- fluid
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004458 analytical method Methods 0.000 title claims abstract description 205
- 238000000034 method Methods 0.000 title claims abstract description 159
- 239000008280 blood Substances 0.000 claims abstract description 246
- 210000004369 blood Anatomy 0.000 claims abstract description 243
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 202
- 238000012360 testing method Methods 0.000 claims abstract description 77
- 238000004163 cytometry Methods 0.000 claims abstract description 21
- 230000002489 hematologic effect Effects 0.000 claims abstract description 21
- 238000001514 detection method Methods 0.000 claims abstract description 20
- 210000004027 cell Anatomy 0.000 claims description 339
- 210000003743 erythrocyte Anatomy 0.000 claims description 207
- 210000000265 leukocyte Anatomy 0.000 claims description 153
- 210000001772 blood platelet Anatomy 0.000 claims description 145
- 230000003287 optical effect Effects 0.000 claims description 138
- 210000001995 reticulocyte Anatomy 0.000 claims description 103
- 230000008569 process Effects 0.000 claims description 48
- 230000009089 cytolysis Effects 0.000 claims description 35
- 238000002156 mixing Methods 0.000 claims description 35
- 238000012546 transfer Methods 0.000 claims description 21
- 230000002934 lysing effect Effects 0.000 claims description 18
- 238000010186 staining Methods 0.000 claims description 14
- 238000000926 separation method Methods 0.000 claims description 10
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical group O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 9
- 238000007865 diluting Methods 0.000 claims description 6
- 239000007850 fluorescent dye Substances 0.000 claims description 6
- 238000001917 fluorescence detection Methods 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims 2
- 238000000569 multi-angle light scattering Methods 0.000 claims 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 4
- 239000000523 sample Substances 0.000 description 468
- 239000012530 fluid Substances 0.000 description 238
- 102000001554 Hemoglobins Human genes 0.000 description 105
- 108010054147 Hemoglobins Proteins 0.000 description 105
- 238000011534 incubation Methods 0.000 description 92
- 238000005259 measurement Methods 0.000 description 86
- 239000000975 dye Substances 0.000 description 73
- 239000000203 mixture Substances 0.000 description 73
- 239000003085 diluting agent Substances 0.000 description 70
- 210000004698 lymphocyte Anatomy 0.000 description 66
- 238000012545 processing Methods 0.000 description 65
- 239000000306 component Substances 0.000 description 37
- 238000002360 preparation method Methods 0.000 description 29
- 238000010586 diagram Methods 0.000 description 27
- 238000003860 storage Methods 0.000 description 26
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 25
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 25
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 25
- 238000004422 calculation algorithm Methods 0.000 description 25
- 230000033001 locomotion Effects 0.000 description 25
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 21
- 239000000872 buffer Substances 0.000 description 20
- 238000010790 dilution Methods 0.000 description 20
- 239000012895 dilution Substances 0.000 description 20
- 238000012384 transportation and delivery Methods 0.000 description 20
- 239000003795 chemical substances by application Substances 0.000 description 19
- 230000004069 differentiation Effects 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 238000000684 flow cytometry Methods 0.000 description 19
- 239000000243 solution Substances 0.000 description 18
- 210000000601 blood cell Anatomy 0.000 description 17
- 239000000463 material Substances 0.000 description 17
- 239000002245 particle Substances 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 16
- 230000002159 abnormal effect Effects 0.000 description 15
- 238000010438 heat treatment Methods 0.000 description 15
- 230000015654 memory Effects 0.000 description 15
- 210000001744 T-lymphocyte Anatomy 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 14
- 230000005856 abnormality Effects 0.000 description 13
- -1 aliphatic aldehyde Chemical class 0.000 description 13
- 210000000207 lymphocyte subset Anatomy 0.000 description 13
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- 239000013610 patient sample Substances 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 239000000427 antigen Substances 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 238000000149 argon plasma sintering Methods 0.000 description 11
- 230000002572 peristaltic effect Effects 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 210000000440 neutrophil Anatomy 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 238000009423 ventilation Methods 0.000 description 10
- 102100022749 Aminopeptidase N Human genes 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 9
- 108010004729 Phycoerythrin Proteins 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 9
- 210000003719 b-lymphocyte Anatomy 0.000 description 9
- 238000004891 communication Methods 0.000 description 9
- 239000006185 dispersion Substances 0.000 description 9
- 210000001616 monocyte Anatomy 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 239000004094 surface-active agent Substances 0.000 description 9
- 238000011144 upstream manufacturing Methods 0.000 description 9
- 239000002699 waste material Substances 0.000 description 9
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 description 8
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 8
- 102100032999 Integrin beta-3 Human genes 0.000 description 8
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 8
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 8
- 210000003651 basophil Anatomy 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 238000005534 hematocrit Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 7
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 7
- 229910052786 argon Inorganic materials 0.000 description 7
- 238000004140 cleaning Methods 0.000 description 7
- 239000012470 diluted sample Substances 0.000 description 7
- 238000004043 dyeing Methods 0.000 description 7
- 210000002751 lymph Anatomy 0.000 description 7
- 230000035800 maturation Effects 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 210000005259 peripheral blood Anatomy 0.000 description 7
- 239000011886 peripheral blood Substances 0.000 description 7
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 238000007405 data analysis Methods 0.000 description 6
- 210000003979 eosinophil Anatomy 0.000 description 6
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 5
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 5
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 150000001447 alkali salts Chemical class 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000012937 correction Methods 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 238000013394 immunophenotyping Methods 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 210000005087 mononuclear cell Anatomy 0.000 description 5
- 239000002736 nonionic surfactant Substances 0.000 description 5
- 229930182490 saponin Natural products 0.000 description 5
- 150000007949 saponins Chemical class 0.000 description 5
- 235000017709 saponins Nutrition 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000004323 axial length Effects 0.000 description 4
- 230000008033 biological extinction Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000003714 granulocyte Anatomy 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- 210000001624 hip Anatomy 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000003924 normoblast Anatomy 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 238000006862 quantum yield reaction Methods 0.000 description 4
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000010963 304 stainless steel Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229910000589 SAE 304 stainless steel Inorganic materials 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000002771 cell marker Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 239000004020 conductor Substances 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 238000013480 data collection Methods 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000000834 fixative Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 230000002101 lytic effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 3
- 229910052753 mercury Inorganic materials 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 210000004976 peripheral blood cell Anatomy 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 235000015497 potassium bicarbonate Nutrition 0.000 description 3
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 3
- 239000011736 potassium bicarbonate Substances 0.000 description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 238000012797 qualification Methods 0.000 description 3
- 230000033764 rhythmic process Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- ACOJCCLIDPZYJC-UHFFFAOYSA-M thiazole orange Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.C1=CC=C2C(C=C3N(C4=CC=CC=C4S3)C)=CC=[N+](C)C2=C1 ACOJCCLIDPZYJC-UHFFFAOYSA-M 0.000 description 3
- 238000002834 transmittance Methods 0.000 description 3
- ZWEVPYNPHSPIFU-AUGHYPCGSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxy-n-[3-[3-[[(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoyl]amino]propyl-[(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenan Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)N(CCCNC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)CCCNC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)C)[C@@]2(C)[C@@H](O)C1 ZWEVPYNPHSPIFU-AUGHYPCGSA-N 0.000 description 2
- BGWLYQZDNFIFRX-UHFFFAOYSA-N 5-[3-[2-[3-(3,8-diamino-6-phenylphenanthridin-5-ium-5-yl)propylamino]ethylamino]propyl]-6-phenylphenanthridin-5-ium-3,8-diamine;dichloride Chemical compound [Cl-].[Cl-].C=1C(N)=CC=C(C2=CC=C(N)C=C2[N+]=2CCCNCCNCCC[N+]=3C4=CC(N)=CC=C4C4=CC=C(N)C=C4C=3C=3C=CC=CC=3)C=1C=2C1=CC=CC=C1 BGWLYQZDNFIFRX-UHFFFAOYSA-N 0.000 description 2
- NFPWWZIRTMIQKT-UHFFFAOYSA-N 6-amino-4-(3,5-dichloro-2-hydroxyphenyl)-3-propyl-2,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile Chemical compound C12=C(CCC)NN=C2OC(N)=C(C#N)C1C1=CC(Cl)=CC(Cl)=C1O NFPWWZIRTMIQKT-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 108010041397 CD4 Antigens Proteins 0.000 description 2
- 101100244387 Candida albicans (strain SC5314 / ATCC MYA-2876) PMT6 gene Proteins 0.000 description 2
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 241000406668 Loxodonta cyclotis Species 0.000 description 2
- 101150036326 PMT2 gene Proteins 0.000 description 2
- 101150024216 PMT3 gene Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 101100241858 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OAC1 gene Proteins 0.000 description 2
- 101100043108 Schizosaccharomyces pombe (strain 972 / ATCC 24843) spb1 gene Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000003969 blast cell Anatomy 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 210000004970 cd4 cell Anatomy 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 210000003593 megakaryocyte Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- UMWKZHPREXJQGR-XOSAIJSUSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]decanamide Chemical compound CCCCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO UMWKZHPREXJQGR-XOSAIJSUSA-N 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000012758 nuclear staining Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000011295 pitch Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 101150092906 pmt1 gene Proteins 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000013022 venting Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- JDRSMPFHFNXQRB-IWQYDBTJSA-N (3r,4s,5s,6r)-2-decoxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound CCCCCCCCCCOC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JDRSMPFHFNXQRB-IWQYDBTJSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- DKDLKQQSQNGTNX-UHFFFAOYSA-N 2-[2,2-bis(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCCC1(CCO)CNCCN1CCS(O)(=O)=O DKDLKQQSQNGTNX-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 229910000619 316 stainless steel Inorganic materials 0.000 description 1
- XERBEDAMDXRGFD-UHFFFAOYSA-N 6-(2-chlorophenyl)-5-pentanoyl-8,9,10,11-tetrahydro-6h-benzo[b][1,4]benzodiazepin-7-one Chemical compound C1CCC(=O)C2=C1NC1=CC=CC=C1N(C(=O)CCCC)C2C1=CC=CC=C1Cl XERBEDAMDXRGFD-UHFFFAOYSA-N 0.000 description 1
- CLMQBVUFKIKYLU-UHFFFAOYSA-N 6-amino-4-(2,5-dimethoxyphenyl)-3-naphthalen-2-yl-2,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile Chemical compound COC1=CC=C(OC)C(C2C(=C(N)OC=3C2=C(NN=3)C=2C=C3C=CC=CC3=CC=2)C#N)=C1 CLMQBVUFKIKYLU-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N Azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 210000003359 CD4-positive helper T lymphocyte Anatomy 0.000 description 1
- 108010032795 CD8 receptor Proteins 0.000 description 1
- 101100327917 Caenorhabditis elegans chup-1 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 101001123534 Nicotiana tabacum Putrescine N-methyltransferase 2 Proteins 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- DPXHITFUCHFTKR-UHFFFAOYSA-L To-Pro-1 Chemical compound [I-].[I-].S1C2=CC=CC=C2[N+](C)=C1C=C1C2=CC=CC=C2N(CCC[N+](C)(C)C)C=C1 DPXHITFUCHFTKR-UHFFFAOYSA-L 0.000 description 1
- MZZINWWGSYUHGU-UHFFFAOYSA-J ToTo-1 Chemical compound [I-].[I-].[I-].[I-].C12=CC=CC=C2C(C=C2N(C3=CC=CC=C3S2)C)=CC=[N+]1CCC[N+](C)(C)CCC[N+](C)(C)CCC[N+](C1=CC=CC=C11)=CC=C1C=C1N(C)C2=CC=CC=C2S1 MZZINWWGSYUHGU-UHFFFAOYSA-J 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 208000019513 White blood cell disease Diseases 0.000 description 1
- ULHRKLSNHXXJLO-UHFFFAOYSA-L Yo-Pro-1 Chemical compound [I-].[I-].C1=CC=C2C(C=C3N(C4=CC=CC=C4O3)C)=CC=[N+](CCC[N+](C)(C)C)C2=C1 ULHRKLSNHXXJLO-UHFFFAOYSA-L 0.000 description 1
- GRRMZXFOOGQMFA-UHFFFAOYSA-J YoYo-1 Chemical compound [I-].[I-].[I-].[I-].C12=CC=CC=C2C(C=C2N(C3=CC=CC=C3O2)C)=CC=[N+]1CCC[N+](C)(C)CCC[N+](C)(C)CCC[N+](C1=CC=CC=C11)=CC=C1C=C1N(C)C2=CC=CC=C2O1 GRRMZXFOOGQMFA-UHFFFAOYSA-J 0.000 description 1
- JSBNEYNPYQFYNM-UHFFFAOYSA-J YoYo-3 Chemical compound [I-].[I-].[I-].[I-].C12=CC=CC=C2C(C=CC=C2N(C3=CC=CC=C3O2)C)=CC=[N+]1CCC(=[N+](C)C)CCCC(=[N+](C)C)CC[N+](C1=CC=CC=C11)=CC=C1C=CC=C1N(C)C2=CC=CC=C2O1 JSBNEYNPYQFYNM-UHFFFAOYSA-J 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- RRUDCFGSUDOHDG-UHFFFAOYSA-N acetohydroxamic acid Chemical compound CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 description 1
- 239000012042 active reagent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000006117 anti-reflective coating Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000006177 biological buffer Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 239000001058 brown pigment Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 239000005331 crown glasses (windows) Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
- QCUPYFTWJOZAOB-HYXAFXHYSA-N ectylurea Chemical compound CC\C(=C\C)C(=O)NC(N)=O QCUPYFTWJOZAOB-HYXAFXHYSA-N 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000007772 electrode material Substances 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 229920006333 epoxy cement Polymers 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000005308 flint glass Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 208000034737 hemoglobinopathy Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- HQRPHMAXFVUBJX-UHFFFAOYSA-M lithium;hydrogen carbonate Chemical compound [Li+].OC([O-])=O HQRPHMAXFVUBJX-UHFFFAOYSA-M 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- IBIKHMZPHNKTHM-RDTXWAMCSA-N merck compound 25 Chemical compound C1C[C@@H](C(O)=O)[C@H](O)CN1C(C1=C(F)C=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C1CC1 IBIKHMZPHNKTHM-RDTXWAMCSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940111688 monobasic potassium phosphate Drugs 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229940005654 nitrite ion Drugs 0.000 description 1
- 239000012811 non-conductive material Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000009428 plumbing Methods 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 229940093916 potassium phosphate Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000012780 transparent material Substances 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- XJCQPMRCZSJDPA-UHFFFAOYSA-L trimethyl-[3-[4-[(e)-(3-methyl-1,3-benzothiazol-2-ylidene)methyl]pyridin-1-ium-1-yl]propyl]azanium;diiodide Chemical compound [I-].[I-].S1C2=CC=CC=C2N(C)\C1=C\C1=CC=[N+](CCC[N+](C)(C)C)C=C1 XJCQPMRCZSJDPA-UHFFFAOYSA-L 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/10—Devices for transferring samples or any liquids to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
- G01N35/1095—Devices for transferring samples or any liquids to, in, or from, the analysis apparatus, e.g. suction devices, injection devices for supplying the samples to flow-through analysers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F25/00—Flow mixers; Mixers for falling materials, e.g. solid particles
- B01F25/30—Injector mixers
- B01F25/31—Injector mixers in conduits or tubes through which the main component flows
- B01F25/313—Injector mixers in conduits or tubes through which the main component flows wherein additional components are introduced in the centre of the conduit
- B01F25/3132—Injector mixers in conduits or tubes through which the main component flows wherein additional components are introduced in the centre of the conduit by using two or more injector devices
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F25/00—Flow mixers; Mixers for falling materials, e.g. solid particles
- B01F25/30—Injector mixers
- B01F25/31—Injector mixers in conduits or tubes through which the main component flows
- B01F25/313—Injector mixers in conduits or tubes through which the main component flows wherein additional components are introduced in the centre of the conduit
- B01F25/3132—Injector mixers in conduits or tubes through which the main component flows wherein additional components are introduced in the centre of the conduit by using two or more injector devices
- B01F25/31324—Injector mixers in conduits or tubes through which the main component flows wherein additional components are introduced in the centre of the conduit by using two or more injector devices arranged concentrically
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Electro-optical investigation, e.g. flow cytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Electro-optical investigation, e.g. flow cytometers
- G01N15/1404—Fluid conditioning in flow cytometers, e.g. flow cells; Supply; Control of flow
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/00584—Control arrangements for automatic analysers
- G01N35/0092—Scheduling
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/10—Devices for transferring samples or any liquids to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
- G01N35/1004—Cleaning sample transfer devices
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/10—Devices for transferring samples or any liquids to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
- G01N35/1081—Devices for transferring samples or any liquids to, in, or from, the analysis apparatus, e.g. suction devices, injection devices characterised by the means for relatively moving the transfer device and the containers in an horizontal plane
- G01N35/109—Devices for transferring samples or any liquids to, in, or from, the analysis apparatus, e.g. suction devices, injection devices characterised by the means for relatively moving the transfer device and the containers in an horizontal plane with two horizontal degrees of freedom
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/02—Devices for withdrawing samples
- G01N1/10—Devices for withdrawing samples in the liquid or fluent state
- G01N1/14—Suction devices, e.g. pumps; Ejector devices
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Electro-optical investigation, e.g. flow cytometers
- G01N15/1456—Electro-optical investigation, e.g. flow cytometers without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
- G01N15/1459—Electro-optical investigation, e.g. flow cytometers without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
-
- G01N2015/011—
-
- G01N2015/014—
-
- G01N2015/018—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Electro-optical investigation, e.g. flow cytometers
- G01N15/1404—Fluid conditioning in flow cytometers, e.g. flow cells; Supply; Control of flow
- G01N2015/1413—Hydrodynamic focussing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N2035/00346—Heating or cooling arrangements
- G01N2035/00356—Holding samples at elevated temperature (incubation)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N2035/00465—Separating and mixing arrangements
- G01N2035/00524—Mixing by agitating sample carrier
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/10—Devices for transferring samples or any liquids to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
- G01N2035/1027—General features of the devices
- G01N2035/1032—Dilution or aliquotting
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/10—Devices for transferring samples or any liquids to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/973—Simultaneous determination of more than one analyte
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/805—Optical property
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/11—Automated chemical analysis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25125—Digestion or removing interfering materials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/2575—Volumetric liquid transfer
Landscapes
- Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. (a)全血サンプルを提供する工程; (b)全血サンプルについて行われる二またはそれ以上の一連の試験を選択し、 全血サンプルについて行われる試験を関連付ける工程; (c)第1の量の全血サンプルを、全血サンプルについて従来の血液学的分析と 蛍光サイトメトリー分析を行うことのできる自動装置システム内に吸引する工程 ; (d)装置が、少なくとも3つのサンプル受け入れ容器内に全血サンプルのアリ コートを分配する工程; (e)装置が、第1のアリコートの全血サンプルを希釈試薬で希釈する工程; (f)装置が、第2のアリコートの全血サンプルを溶解試薬で溶解する工程; (g)装置が、第3のアリコートの全血サンプルを蛍光試薬と混合する工程; (h)装置が、第1のアリコートの希釈全血サンプルをフロートランスデューサ ーを通して輸送する工程; (i)装置のフロートランスデューサーが、第1のアリコートの希釈全血サンプ ル中の赤血球および血小板を検出および計数する工程; (j)装置が、第2のアリコートの溶解全血サンプルをフロートランスデューサ ーシステムを通して輸送する工程; (k)フロートランスデューサーシステムが、第2のアリコートの溶解全血サン プルから多角光散乱を検出し、第2のアリコートの全血サンプル中の白血球を計 数および識別する工程; (l)フロートランスデューサーシステムが、第2のアリコートの溶解全血サン プルまたは第1のアリコートの希釈全血サンプルからの多角光散乱および蛍光を 検出し、その中の有核赤血球もしくは網状赤血球または両者を計数および識別す る工程; (m)装置が、第3のアリコートの全血サンプルをフロートランスデューサーシ ステムを通して輸送する工程; (n)フロートランスデューサーシステムが、第3のアリコートの全血サンプル からの多角光散乱および蛍光を検出し、その中の血小板もしくは凝集血小板また は両者を計数および識別する工程; (o)装置が、全血サンプルについて行われる複数試験につい てのデータを貯蔵、検出および識別する工程; (p)装置が、全血サンプルについて行われる複数試験の各々の結果を、必要な らば定量的に報告する工程; を含んでなる、全血サンプル中の細胞を区別および識別する自動的方法であって 、 ここで、装置システムは、細胞を全血サンプルまたはそのアリコートから物理 的に分離することなく全ての工程を自動的に行い、従来法の血液学的分析の結果 は、少なくとも蛍光サイトメトリー試験の結果の報告において利用することがで きる方法。 2. さらに (q)第1のアリコートの全血サンプルを染色する工程;および (r)染色された第1のアリコートの全血サンプルをフロートランスデューサー システムを通して輸送し、そこで網状赤血球を計数および染色された第1のアリ コートの全血サンプルから識別する工程 を含む請求項1に記載の方法。 3. 装置フロートランスデューサーシステムがインピーダンスフローセルを含 む請求項1に記載の方法。 4. インピーダンストランスデューサー検出データを利用して定量的赤血球お よび血小板の結果を提供する請求項1に記載の方法。 5. 第1のアリコートの全血サンプルが、装置により、光学的フローセルトラ ンスデューサーシステムを通して輸送され、多角光散乱が検出されて第1のアリ コートの全血サンプル中の血小板を計数および識別する請求項1に記載の方法。 6. 蛍光試薬が、一またはそれ以上の蛍光色素と結合された一またはそれ以上 のモノクローナル抗体を含んでなる請求項1に記載の方法。 7. モノクローナル抗体の一つが抗CD61であり、蛍光色素がFITCであ る請求項6に記載の方法。 8. 報告された定量的血小板の結果が、多角光散乱および蛍光検出データから 得られる詰求項1に記載の自動的方法。 9. 混合すべき全血サンプルの受け入れ容器が、一またはそれ以上のモノクロ ーナル抗体と結合された予め測定された量の一またはそれ以上のモノクローナル 抗体を含む使い捨て容器である請求項1に記載の方法。 10. (a)全血サンプルを提供する工程; (b)全血サンプルについて行われる一またはそれ以上の一連の試験を選択する 工程; (c)全血サンプルについて行われる試験を関連付ける工程; (d)所定量の全血サンプルを、全血サンプルについて従来の血液学的分析と蛍 光サイトメトリー分析を自動的に行うことのできる自動装置システム内に吸引す る工程; (e)装置が、少なくとも1つのサンプル受け入れ容器内に第1のアリコートの 全血サンプルを分配する工程; (f)装置が、第1のアリコートの全血サンプルを蛍光試薬と混合する工程; (g)装置が、蛍光試薬と混合された第1のアリコートの全血サンプルを希釈お よびフロートランスデューサーシステムを通してを輸送する工程; (h)フロートランスデューサーシステムが、蛍光試薬と混合された第1のアリ コートの全血サンプルからの多角光散乱および蛍光を検出し、その中の血小板も しくは凝集血小板または両者を計数および識別する工程; (i)装置が、全血サンプルについて行われる一またはそれ以上の試験について のデータを貯蔵、検出および識別する工程; (j)装置が、全血サンプルについて行われる一またはそれ以上の試験の各々の 結果を、必要ならば定量的に報告する工程; を含んでなる、全血サンプル中の細胞を区別および識別する自動的方法であって 、 ここで、装置システムは、細胞を全血サンプルまたはそのアリコートから物理 的に分離することなく全ての工程を自動的に行い、従来法の血液学的分析の結果 は、少なくとも蛍光サイトメトリー試験の結果の報告において利用することがで きる方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/682,334 | 1996-07-17 | ||
US08/682,334 US5891734A (en) | 1994-08-01 | 1996-07-17 | Method for performing automated analysis |
PCT/US1997/011105 WO1998002727A1 (en) | 1996-07-17 | 1997-06-26 | Method and apparatus for performing automated analysis |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002503333A true JP2002503333A (ja) | 2002-01-29 |
JP3701977B2 JP3701977B2 (ja) | 2005-10-05 |
Family
ID=24739238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50604198A Expired - Lifetime JP3701977B2 (ja) | 1996-07-17 | 1997-06-26 | 自動分析実施方法および装置 |
Country Status (5)
Country | Link |
---|---|
US (1) | US5891734A (ja) |
EP (1) | EP0912885A1 (ja) |
JP (1) | JP3701977B2 (ja) |
CA (1) | CA2258603C (ja) |
WO (1) | WO1998002727A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4755253B2 (ja) * | 2005-08-24 | 2011-08-24 | ベックマン コールター, インコーポレイテッド | 血液試料における赤血球の正確な測定 |
JP2012519848A (ja) * | 2009-03-04 | 2012-08-30 | ベックマン コールター, インコーポレイテッド | 細胞集団識別のための機器間の方法およびシステム |
JP2015500999A (ja) * | 2011-12-21 | 2015-01-08 | ベックマン コールター, インコーポレイテッド | 白血球の細胞内標的及び細胞外標的の標識方法 |
Families Citing this family (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6509192B1 (en) * | 1992-02-24 | 2003-01-21 | Coulter International Corp. | Quality control method |
DE69830598T2 (de) * | 1997-01-31 | 2006-05-18 | The Horticulture And Food Research Institute Of New Zealand Limited | Optische vorrichtung und methode |
US6149867A (en) | 1997-12-31 | 2000-11-21 | Xy, Inc. | Sheath fluids and collection systems for sex-specific cytometer sorting of sperm |
CA2338194C (en) | 1998-07-30 | 2013-09-10 | Edward L. Squires | Equine system for non-surgical artificial insemination |
US7208265B1 (en) * | 1999-11-24 | 2007-04-24 | Xy, Inc. | Method of cryopreserving selected sperm cells |
CA2408939C (en) * | 2000-05-09 | 2011-11-08 | Xy, Inc. | High purity x-chromosome bearing and y-chromosome bearing populations of spermatozoa |
CA2411462A1 (en) * | 2000-06-12 | 2001-12-20 | Colorado State University Research Foundation | Integrated herd management system utilizing isolated populations of x-chromosome bearing and y-chromosome bearing spermatozoa |
US7713687B2 (en) | 2000-11-29 | 2010-05-11 | Xy, Inc. | System to separate frozen-thawed spermatozoa into x-chromosome bearing and y-chromosome bearing populations |
AU2002220018A1 (en) | 2000-11-29 | 2002-06-11 | Colorado State University | System for in-vitro fertilization with spermatozoa separated into x-chromosome and y-chromosome bearing populations |
US8775196B2 (en) | 2002-01-29 | 2014-07-08 | Baxter International Inc. | System and method for notification and escalation of medical data |
US10173008B2 (en) | 2002-01-29 | 2019-01-08 | Baxter International Inc. | System and method for communicating with a dialysis machine through a network |
AR035231A1 (es) * | 2002-03-11 | 2004-05-05 | Ypf S A | Un equipo para analizar el crecimiento de microorganismos y procedimiento para cuantificar la concentracion de microorganismos |
US7718072B2 (en) * | 2002-04-26 | 2010-05-18 | Abbott Laboratories | Structure and method for handling magnetic particles in biological assays |
US8234128B2 (en) | 2002-04-30 | 2012-07-31 | Baxter International, Inc. | System and method for verifying medical device operational parameters |
US8486618B2 (en) | 2002-08-01 | 2013-07-16 | Xy, Llc | Heterogeneous inseminate system |
MXPA05001100A (es) | 2002-08-01 | 2005-04-28 | Xy Inc | Sistema de separacion de baja presion para celulas de esperma. |
WO2004017041A2 (en) | 2002-08-15 | 2004-02-26 | Xy, Inc. | High resolution flow cytometer |
US7169548B2 (en) | 2002-09-13 | 2007-01-30 | Xy, Inc. | Sperm cell processing and preservation systems |
US20040088189A1 (en) * | 2002-11-06 | 2004-05-06 | Veome Edmond A. | System and method for monitoring , reporting, managing and administering the treatment of a blood component |
DK2309245T3 (en) | 2003-03-28 | 2016-01-04 | Inguran Llc | Methods for providing sex-sorted animal semen |
NZ544103A (en) | 2003-05-15 | 2010-10-29 | Xy Llc | Efficient haploid cell sorting for flow cytometer systems |
EP2151243B1 (en) | 2004-03-29 | 2012-10-24 | Inguran, LLC | Sperm suspensions for sorting into X or Y chromosome-bearing enriched populations |
WO2006085897A2 (en) * | 2004-05-13 | 2006-08-17 | Advanced Animal Diagnostics | Microfluidic device and leucocyte antigen mediated microfluidic assay |
US7390662B2 (en) * | 2005-11-09 | 2008-06-24 | Beckman Coulter, Inc. | Method and apparatus for performing platelet measurement |
CA2574499C (en) | 2004-07-22 | 2016-11-29 | Monsanto Technology Llc | Process for enriching a population of sperm cells |
ES2445148T3 (es) * | 2004-09-01 | 2014-02-28 | Maine Standards Company Llc | Patrones de lípidos estables novedosos |
US7635594B2 (en) | 2005-05-09 | 2009-12-22 | Theranos, Inc. | Point-of-care fluidic systems and uses thereof |
US20070025879A1 (en) * | 2005-07-27 | 2007-02-01 | Dakocytomation Denmark A/S | Method and apparatus for syringe-based sample introduction within a flow cytometer |
US9424392B2 (en) | 2005-11-26 | 2016-08-23 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
US7618770B2 (en) * | 2005-07-29 | 2009-11-17 | Xy, Inc. | Methods and apparatus for reducing protein content in sperm cell extenders |
US11287421B2 (en) | 2006-03-24 | 2022-03-29 | Labrador Diagnostics Llc | Systems and methods of sample processing and fluid control in a fluidic system |
US8007999B2 (en) | 2006-05-10 | 2011-08-30 | Theranos, Inc. | Real-time detection of influenza virus |
WO2008024778A1 (en) * | 2006-08-21 | 2008-02-28 | Anp Technologies, Inc. | Automated self-contained liquid handling and detection system device |
US8012744B2 (en) | 2006-10-13 | 2011-09-06 | Theranos, Inc. | Reducing optical interference in a fluidic device |
US20090051372A1 (en) * | 2006-10-30 | 2009-02-26 | Palaniappan Sethu | 3D fluid confined sample stream coulter flow cytometry |
US20080113391A1 (en) | 2006-11-14 | 2008-05-15 | Ian Gibbons | Detection and quantification of analytes in bodily fluids |
CN101236150B (zh) * | 2007-02-02 | 2012-09-05 | 深圳迈瑞生物医疗电子股份有限公司 | 用于基于流式细胞术的仪器的光电传感器及其照射单元 |
US20090027998A1 (en) * | 2007-07-25 | 2009-01-29 | Abbott Laboratories | Magnetic mixer |
US8158430B1 (en) | 2007-08-06 | 2012-04-17 | Theranos, Inc. | Systems and methods of fluidic sample processing |
CA2934220C (en) | 2007-10-02 | 2019-11-05 | Theranos, Inc. | Modular point-of-care devices and uses thereof |
US20090129990A1 (en) * | 2007-11-16 | 2009-05-21 | Abbott Laboratories | Rack for sample containers for clinical analyzer |
US7678331B2 (en) * | 2007-12-20 | 2010-03-16 | Abbott Laboratories Inc. | Automatic loading of sample tubes for clinical analyzer |
CA2718992C (en) | 2008-03-21 | 2013-04-30 | Abbott Point Of Care, Inc. | Method and apparatus for determining the hematocrit of a blood sample utilizing the intrinsic pigmentation of hemoglobin contained within the red blood cells |
CN102016686B (zh) | 2008-03-21 | 2015-03-25 | 艾博特健康公司 | 确定对生物样本成像的成像装置的焦点位置的方法和设备 |
CN102027368B (zh) | 2008-03-21 | 2014-02-26 | 艾博特健康公司 | 利用红细胞内含有的血红蛋白的本征色素沉着来确定血样的红细胞指数的方法及设备 |
EP2271937B1 (en) | 2008-03-21 | 2016-01-13 | Abbott Point Of Care, Inc. | Method and apparatus for detecting and counting platelets individually and in aggregate clumps |
WO2009117683A2 (en) | 2008-03-21 | 2009-09-24 | Abbott Point Of Care | Method and apparatus for analyzing individual cells or particulates using fluorescent quenching and/or bleaching |
JP5189201B2 (ja) | 2008-04-02 | 2013-04-24 | アボット ポイント オブ ケア インコーポレイテッド | 全血を含む生体体液のイムノアッセイを実施するためのリガンドアッセイにおける結合標識と遊離標識との仮想分離 |
US8326008B2 (en) | 2008-04-09 | 2012-12-04 | Abbott Point Of Care, Inc. | Method for measuring the area of a sample disposed within an analysis chamber |
US7897907B1 (en) | 2008-04-24 | 2011-03-01 | The United States Of America As Represented By The Secretary Of The Navy | System and method for increasing signal-to-noise ratio in optical-based sensor systems |
CA2720132C (en) | 2008-05-06 | 2014-04-08 | Colgate-Palmolive Company | Method of measuring effects of components on cell reactive oxygen species production |
US8057679B2 (en) | 2008-07-09 | 2011-11-15 | Baxter International Inc. | Dialysis system having trending and alert generation |
US10089443B2 (en) | 2012-05-15 | 2018-10-02 | Baxter International Inc. | Home medical device systems and methods for therapy prescription and tracking, servicing and inventory |
US7940105B2 (en) * | 2008-08-08 | 2011-05-10 | Beckman Coulter, Inc. | High-resolution parametric signal restoration |
US8554579B2 (en) | 2008-10-13 | 2013-10-08 | Fht, Inc. | Management, reporting and benchmarking of medication preparation |
US8753290B2 (en) * | 2009-03-27 | 2014-06-17 | Intellectual Inspiration, Llc | Fluid transfer system and method |
FR2945126B1 (fr) * | 2009-04-29 | 2019-11-01 | Commissariat A L'energie Atomique | Procede et appareil de comptage des thrombocytes |
KR20180078345A (ko) | 2009-10-19 | 2018-07-09 | 테라노스, 인코포레이티드 | 통합형 건강 정보 취득 및 분석 시스템 |
ES2438841T3 (es) | 2009-12-31 | 2014-01-20 | Abbott Point Of Care, Inc. | Método y aparato para determinar el volumen celular medio de los glóbulos rojos en la sangre |
WO2011116305A1 (en) | 2010-03-18 | 2011-09-22 | Abbott Point Of Care, Inc. | Method and apparatus for optically determining at least one hemoglobin related parameter of a whole blood sample |
CN101825534B (zh) * | 2010-04-19 | 2012-08-15 | 河北省电力研究院 | 一种油样混合振荡装置 |
US20190010543A1 (en) | 2010-05-18 | 2019-01-10 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11332785B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11322224B2 (en) | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US10316362B2 (en) | 2010-05-18 | 2019-06-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
AU2011255641A1 (en) | 2010-05-18 | 2012-12-06 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11408031B2 (en) | 2010-05-18 | 2022-08-09 | Natera, Inc. | Methods for non-invasive prenatal paternity testing |
US11339429B2 (en) | 2010-05-18 | 2022-05-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11326208B2 (en) | 2010-05-18 | 2022-05-10 | Natera, Inc. | Methods for nested PCR amplification of cell-free DNA |
US9677118B2 (en) | 2014-04-21 | 2017-06-13 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11332793B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for simultaneous amplification of target loci |
WO2011159708A1 (en) * | 2010-06-14 | 2011-12-22 | Accuri Cytometers, Inc. | System and method for creating a flow cytometer network |
CN103168225B (zh) | 2010-10-25 | 2015-11-25 | 阿库里赛托梅特斯公司 | 用于收集流式细胞仪中的数据集的系统和用户接口 |
AR085087A1 (es) | 2011-01-21 | 2013-09-11 | Theranos Inc | Sistemas y metodos para maximizar el uso de muestras |
AU2012242587B2 (en) | 2011-04-15 | 2015-11-26 | Roche Diagnostics Hematology, Inc. | Measuring volume and constituents of cells |
WO2012151103A2 (en) | 2011-05-04 | 2012-11-08 | Abbott Laboratories | Nucleated red blood cell analysis system and method |
EP2705135B1 (en) | 2011-05-04 | 2019-10-30 | Abbott Laboratories | Basophil analysis method |
WO2012151102A2 (en) | 2011-05-04 | 2012-11-08 | Abbott Laboratories | White blood cell analysis system and method |
FI20115785A0 (fi) | 2011-08-08 | 2011-08-08 | Thermo Fisher Scientific Oy | Menetelmä ja laite automaattiseen analyysiin |
US9891149B2 (en) * | 2011-08-08 | 2018-02-13 | Thermo Fisher Scientific Oy | Method and apparatus for automated analysis |
EP2861957B1 (en) | 2012-06-14 | 2018-05-09 | Bio-rad Laboratories, Inc. | Flow rate balanced, dynamically adjustable sheath delivery system for flow cytometry |
WO2013192401A1 (en) * | 2012-06-22 | 2013-12-27 | Bio-Rad Laboratories, Inc. | Fluid mixing and rinsing system for a flow cytometer |
SG11201501427PA (en) | 2012-08-31 | 2015-03-30 | Baxter Corp Englewood | Medication requisition fulfillment system and method |
WO2014065871A2 (en) | 2012-10-26 | 2014-05-01 | Baxter Corporation Englewood | Improved image acquisition for medical dose preparation system |
EP3453377A1 (en) | 2012-10-26 | 2019-03-13 | Baxter Corporation Englewood | Improved work station for medical dose preparation system |
CN104755905B (zh) * | 2012-12-31 | 2018-07-03 | 贝克曼考尔特公司 | 具有凝集块校准的血小板计数的系统和方法 |
EP2939000A1 (en) | 2012-12-31 | 2015-11-04 | Beckman Coulter, Inc. | Immature platelet enumeration systems and methods |
AU2014305889B2 (en) * | 2013-08-08 | 2017-06-29 | Illumina, Inc. | Fluidic system for reagent delivery to a flow cell |
JP6116502B2 (ja) * | 2014-02-28 | 2017-04-19 | シスメックス株式会社 | 検体分析装置および検体分析方法 |
RU2717641C2 (ru) | 2014-04-21 | 2020-03-24 | Натера, Инк. | Обнаружение мутаций и плоидности в хромосомных сегментах |
CA2953392A1 (en) | 2014-06-30 | 2016-01-07 | Baxter Corporation Englewood | Managed medical information exchange |
US9766105B2 (en) * | 2014-07-02 | 2017-09-19 | Cnh Industrial America Llc | Device and method for detecting blockages in an agricultural sprayer |
US11575673B2 (en) | 2014-09-30 | 2023-02-07 | Baxter Corporation Englewood | Central user management in a distributed healthcare information management system |
US11107574B2 (en) | 2014-09-30 | 2021-08-31 | Baxter Corporation Englewood | Management of medication preparation with formulary management |
US20170328924A1 (en) | 2014-11-26 | 2017-11-16 | Ronald Jones | Automated microscopic cell analysis |
US10625259B1 (en) | 2014-11-26 | 2020-04-21 | Medica Corporation | Automated microscopic cell analysis |
US11478789B2 (en) | 2014-11-26 | 2022-10-25 | Medica Corporation | Automated microscopic cell analysis |
AU2015358483A1 (en) | 2014-12-05 | 2017-06-15 | Baxter Corporation Englewood | Dose preparation data analytics |
SG10202107686XA (en) | 2015-03-03 | 2021-08-30 | Baxter Corp Englewood | Pharmacy workflow management with integrated alerts |
JP6542557B2 (ja) * | 2015-03-27 | 2019-07-10 | シスメックス株式会社 | 血液測定装置および血液測定装置の制御方法 |
WO2016183106A1 (en) | 2015-05-11 | 2016-11-17 | Natera, Inc. | Methods and compositions for determining ploidy |
EP3314488B1 (en) | 2015-06-25 | 2024-03-13 | Gambro Lundia AB | Medical device system and method having a distributed database |
US11485996B2 (en) | 2016-10-04 | 2022-11-01 | Natera, Inc. | Methods for characterizing copy number variation using proximity-litigation sequencing |
DE102016120726A1 (de) * | 2016-10-28 | 2018-05-03 | Als Automated Lab Solutions Gmbh | Vorrichtung und Verfahren zur Behandlung biologische Zellen enthaltender Proben, insbesondere von Blut- oder Zellproben |
US10011870B2 (en) | 2016-12-07 | 2018-07-03 | Natera, Inc. | Compositions and methods for identifying nucleic acid molecules |
US11516183B2 (en) | 2016-12-21 | 2022-11-29 | Gambro Lundia Ab | Medical device system including information technology infrastructure having secure cluster domain supporting external domain |
GB201704747D0 (en) * | 2017-01-05 | 2017-05-10 | Illumina Inc | Reagent mixing system and methods |
CN108303363B (zh) * | 2017-01-12 | 2023-08-22 | 长春市布拉泽医疗科技有限公司 | 一种血细胞分析方法及使用该方法的血细胞分析仪 |
US11725227B2 (en) * | 2017-08-01 | 2023-08-15 | Essenlix Corporation | Devices and methods for examining drug effects on microorganisms |
CN111033256B (zh) * | 2017-09-05 | 2022-07-12 | 深圳迈瑞生物医疗电子股份有限公司 | 血小板聚集样本的报警方法、血细胞分析仪及存储介质 |
US11047845B1 (en) | 2017-11-15 | 2021-06-29 | Medica Corporation | Control material and methods for cell analyzers |
WO2019206312A1 (zh) * | 2018-04-28 | 2019-10-31 | 深圳迈瑞生物医疗电子股份有限公司 | 样本分析仪异常的报警方法、系统及存储介质 |
CN110609139B (zh) * | 2018-06-14 | 2023-06-30 | 深圳市理邦精密仪器股份有限公司 | 抗原浓度过量检测方法、装置及存储介质 |
US11525159B2 (en) | 2018-07-03 | 2022-12-13 | Natera, Inc. | Methods for detection of donor-derived cell-free DNA |
WO2020023906A2 (en) * | 2018-07-27 | 2020-01-30 | Vaxess Technologies, Inc. | Polymer-based biospecimen collection devices and uses thereof |
WO2020133285A1 (zh) * | 2018-12-28 | 2020-07-02 | 深圳迈瑞生物医疗电子股份有限公司 | 一种血液细胞参数修正方法、血液样本检测仪和存储介质 |
CN111712703B (zh) * | 2019-11-18 | 2024-04-12 | 深圳迈瑞生物医疗电子股份有限公司 | 样本分析仪及样本分析方法 |
JP7365504B2 (ja) * | 2020-05-19 | 2023-10-19 | ライフ テクノロジーズ コーポレーション | フローサイトメータ用のノズルシールおよび詰まり除去ステーション |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3770349A (en) * | 1969-03-17 | 1973-11-06 | Sanchez G Legorreta | Method and apparatus for automatically classifying complex, microscopic particles such as human cells |
US3586859A (en) * | 1970-02-16 | 1971-06-22 | Irwin J Katz | Fluorescent cell viability counter |
US4054151A (en) * | 1974-05-20 | 1977-10-18 | Buchler Instruments, Division Of Searle Diagnostics Inc. | Concentrating vortex shaker |
US4053229A (en) * | 1976-01-13 | 1977-10-11 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | 2°/90° Laboratory scattering photometer |
US4577964A (en) * | 1978-09-06 | 1986-03-25 | Ortho Diagnostics, Inc. | Apparatus and method for detecting platelets in whole blood |
US4325910A (en) * | 1979-07-11 | 1982-04-20 | Technicraft, Inc. | Automated multiple-purpose chemical-analysis apparatus |
US4284412A (en) * | 1979-07-13 | 1981-08-18 | Ortho Diagnostics, Inc. | Method and apparatus for automated identification and enumeration of specified blood cell subclasses |
US4265538A (en) * | 1979-10-18 | 1981-05-05 | Leeds & Northrup Company | Optical sample cell for analysis of particles in liquid suspension |
US4463708A (en) * | 1980-05-27 | 1984-08-07 | Gerry Martin E | Fuel and water homogenizer |
US4520110A (en) * | 1981-10-06 | 1985-05-28 | The Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing a phycobiliprotein labeled ligand or receptor |
DE3220879A1 (de) * | 1982-06-03 | 1983-12-08 | Gebr. Liebisch, 4800 Bielefeld | Reagenzglasschuettler zum mischen und aufwirbeln von analysenfluessigkeiten |
US4542104A (en) * | 1983-04-06 | 1985-09-17 | The Board Of Trustees Of The Leland Stanford Jr. Univ. | Phycobiliprotein fluorescent conjugates |
US4599307A (en) * | 1983-07-18 | 1986-07-08 | Becton, Dickinson And Company | Method for elimination of selected cell populations in analytic cytology |
US4710021A (en) * | 1983-10-14 | 1987-12-01 | Sequoia-Turner Corporation | Particulate matter analyzing apparatus and method |
US4751179A (en) * | 1984-05-31 | 1988-06-14 | Coulter Electronics, Inc. | Method and reagents for differential determination of four populations of leukocytes in blood |
US5188935A (en) * | 1984-05-31 | 1993-02-23 | Coulter Electronics, Inc. | Reagent system and method for identification, enumeration and examination of classes and subclasses of blood leukocytes |
US4661913A (en) * | 1984-09-11 | 1987-04-28 | Becton, Dickinson And Company | Apparatus and method for the detection and classification of articles using flow cytometry techniques |
US5380663A (en) * | 1984-12-24 | 1995-01-10 | Caribbean Microparticles Corporation | Automated system for performance analysis and fluorescence quantitation of samples |
US5073497A (en) * | 1989-06-30 | 1991-12-17 | Caribbean Microparticles Corporation | Microbead reference standard and method of adjusting a flow cytometer to obtain reproducible results using the microbeads |
JPS61153546A (ja) * | 1984-12-26 | 1986-07-12 | Canon Inc | 粒子解析装置 |
US4727020A (en) * | 1985-02-25 | 1988-02-23 | Becton, Dickinson And Company | Method for analysis of subpopulations of blood cells |
JPS61274268A (ja) * | 1985-05-30 | 1986-12-04 | Toshiba Corp | 自動化学分析装置 |
US4707251A (en) * | 1985-06-20 | 1987-11-17 | Golden Aluminum Company | Container scanning and accounting device |
US4989977A (en) * | 1985-07-29 | 1991-02-05 | Becton, Dickinson And Company | Flow cytometry apparatus with improved light beam adjustment |
US4978624A (en) * | 1985-09-06 | 1990-12-18 | Technicon Instruments Corporation | Reagent for the determination of a differential white blood cell count |
US4941809A (en) * | 1986-02-13 | 1990-07-17 | Pinkerton Harry E | Valveless positive displacement metering pump |
NL8601000A (nl) * | 1986-04-21 | 1987-11-16 | Jan Greve T H Twente Afdeling | Het gebruik van gepolariseerd licht in stromingscytometrie. |
US4745285A (en) * | 1986-08-21 | 1988-05-17 | Becton Dickinson And Company | Multi-color fluorescence analysis with single wavelength excitation |
GB2198674B (en) * | 1986-12-17 | 1990-01-31 | Metal Box Plc | Resistance welding apparatus |
US5223398A (en) * | 1987-03-13 | 1993-06-29 | Coulter Corporation | Method for screening cells or formed bodies for enumeration of populations expressing selected characteristics |
US5260192A (en) * | 1987-03-13 | 1993-11-09 | Coulter Corporation | Method and apparatus for screening cells or formed bodies with populations expressing selected characteristics utilizing at least one sensing parameter |
US5238812A (en) * | 1987-03-13 | 1993-08-24 | Coulter Corporation | Method and apparatus for rapid mixing of small volumes for enhancing biological reactions |
DE3885021T2 (de) * | 1987-07-14 | 1994-05-19 | Kyoto Daiichi Kagaku Kyoto Kk | Automatische Messmethode für Glycohämoglobin. |
JPS6435345A (en) * | 1987-07-31 | 1989-02-06 | Canon Kk | Particle analyzing device |
US4987086A (en) * | 1987-11-30 | 1991-01-22 | Becton, Dickinson And Company | Method for analysis of subpopulations of cells |
US5385822A (en) * | 1988-05-02 | 1995-01-31 | Zynaxis, Inc. | Methods for detection and quantification of cell subsets within subpopulations of a mixed cell population |
US5047321A (en) * | 1988-06-15 | 1991-09-10 | Becton Dickinson & Co. | Method for analysis of cellular components of a fluid |
US5408307A (en) * | 1988-07-11 | 1995-04-18 | Omron Tateisi Electronics Co. | Cell analyzer |
JPH0663945B2 (ja) * | 1988-08-26 | 1994-08-22 | 株式会社日立製作所 | 攪拌装置 |
US4848917A (en) * | 1988-08-26 | 1989-07-18 | E. I. Du Pont De Nemours And Company | Automatic vortex mixer |
JPH0718785B2 (ja) * | 1988-09-19 | 1995-03-06 | 株式会社日立製作所 | フローセル装置 |
BE1002614A6 (nl) * | 1988-11-24 | 1991-04-09 | Labotics Bv Met Beperkte Aansp | Werkwijze en inrichting voor het verdunnen van samenstellingen. |
US5032381A (en) * | 1988-12-20 | 1991-07-16 | Tropix, Inc. | Chemiluminescence-based static and flow cytometry |
US5038911A (en) * | 1989-02-16 | 1991-08-13 | Rapistan Corporation | Controlled spacing induction from plural lines |
US5015157A (en) * | 1990-01-10 | 1991-05-14 | Dennis Pinkerton | Pump with multi-port discharge |
JP3049254B2 (ja) * | 1990-02-08 | 2000-06-05 | シスメックス株式会社 | 2種類の光源を備えた光学式粒子分析装置 |
JPH0738839Y2 (ja) * | 1990-05-15 | 1995-09-06 | オムロン株式会社 | 流れ式粒子分析装置 |
US5044889A (en) * | 1990-05-16 | 1991-09-03 | Dennis Pinkerton | Phase adjustable metering pump, and method of adjusting the flow rate thereof |
US5204884A (en) * | 1991-03-18 | 1993-04-20 | University Of Rochester | System for high-speed measurement and sorting of particles |
US5191967A (en) * | 1990-10-30 | 1993-03-09 | Rapistan Corp. | Conveyor system having non-singulating accumulation conveyor |
US5208762A (en) * | 1990-12-06 | 1993-05-04 | Baxter International Inc. | Automated prescription vial filling system |
JP3213334B2 (ja) * | 1991-05-14 | 2001-10-02 | シスメックス株式会社 | 尿中の細胞分析装置 |
JP3067849B2 (ja) * | 1991-07-29 | 2000-07-24 | シスメックス株式会社 | 白血球分類計数用試料調製方法 |
JP3048260B2 (ja) * | 1991-07-29 | 2000-06-05 | シスメックス株式会社 | 白血球分類計数用試料調製方法 |
US5315094A (en) * | 1991-09-23 | 1994-05-24 | R. R. Donnelley & Sons Co. | Automated receiving station for inventorying stock items |
US5360739A (en) * | 1991-12-05 | 1994-11-01 | Miles Inc. | Methods for the identification and characterization of reticulocytes in whole blood |
JP3232145B2 (ja) * | 1991-12-27 | 2001-11-26 | シスメックス株式会社 | 網赤血球測定方法 |
CA2087086A1 (en) * | 1992-01-22 | 1993-07-23 | Leon Wmm Terstappen | Multidimensional cell differential analysis |
WO1993016384A1 (en) * | 1992-02-07 | 1993-08-19 | Abbott Laboratories | Method for accurately enumerating and sensitively qualifying heterogeneous cell populations in cytolytic processing conditions |
JP3391451B2 (ja) * | 1992-02-24 | 2003-03-31 | クールター インターナショナル コーポレイション | 白血球類縁体用の血液対照組成物,およびその調製方法および使用方法 |
US5244633A (en) * | 1992-05-22 | 1993-09-14 | Eastman Kodak Company | Analyzer incubator with plural independently driven rings supporting cuvettes |
US5324025A (en) * | 1992-09-18 | 1994-06-28 | Chadwick Charles M | Physical delay buffer for paper items |
US5371585A (en) * | 1992-11-10 | 1994-12-06 | Pacific Scientific Company | Particle detecting instrument with sapphire detecting cell defining a rectangular flow path |
GR940100272A (en) * | 1993-06-08 | 1995-11-29 | Ortho Diagnostic Systems Inc | Three-colour flow cytometry with automatic gating function. |
US5692220A (en) * | 1993-09-02 | 1997-11-25 | Coulter Corporation | Decision support system and method for diagnosis consultation in laboratory hematopathology |
DE69527292T2 (de) * | 1994-08-01 | 2003-02-27 | Abbott Lab | Pseudo-telezentrischer optischer aufbau für ein durchflusszytometrisches analysegerät für blutzellen |
US5623415A (en) * | 1995-02-16 | 1997-04-22 | Smithkline Beecham Corporation | Automated sampling and testing of biological materials |
-
1996
- 1996-07-17 US US08/682,334 patent/US5891734A/en not_active Expired - Lifetime
-
1997
- 1997-06-26 JP JP50604198A patent/JP3701977B2/ja not_active Expired - Lifetime
- 1997-06-26 WO PCT/US1997/011105 patent/WO1998002727A1/en active Application Filing
- 1997-06-26 CA CA002258603A patent/CA2258603C/en not_active Expired - Lifetime
- 1997-06-26 EP EP97933176A patent/EP0912885A1/en not_active Ceased
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4755253B2 (ja) * | 2005-08-24 | 2011-08-24 | ベックマン コールター, インコーポレイテッド | 血液試料における赤血球の正確な測定 |
JP2012519848A (ja) * | 2009-03-04 | 2012-08-30 | ベックマン コールター, インコーポレイテッド | 細胞集団識別のための機器間の方法およびシステム |
US10564089B2 (en) | 2009-03-04 | 2020-02-18 | Beckman Coulter, Inc. | Cross-instrument method and system for cell population discrimination |
JP2015500999A (ja) * | 2011-12-21 | 2015-01-08 | ベックマン コールター, インコーポレイテッド | 白血球の細胞内標的及び細胞外標的の標識方法 |
Also Published As
Publication number | Publication date |
---|---|
WO1998002727A1 (en) | 1998-01-22 |
JP3701977B2 (ja) | 2005-10-05 |
US5891734A (en) | 1999-04-06 |
CA2258603C (en) | 2006-01-03 |
EP0912885A1 (en) | 1999-05-06 |
CA2258603A1 (en) | 1998-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3701977B2 (ja) | 自動分析実施方法および装置 | |
US5656499A (en) | Method for performing automated hematology and cytometry analysis | |
US5631165A (en) | Method for performing automated hematology and cytometry analysis | |
EP0774113B1 (en) | Method and apparatus for performing automated analysis | |
US5812419A (en) | Fully automated analysis method with optical system for blood cell analyzer | |
EP1297334B1 (en) | Method of using a flow cytometry-based hematology system | |
EP1250585B1 (en) | Method and apparatus for analyzing cells in a whole blood sample | |
US20160061711A1 (en) | Apparatus and methods for cellular analysis | |
JP4279900B2 (ja) | 細胞生存率、有核赤血球、および白血球分類の同時分析方法 | |
US10215683B2 (en) | Light scatter based apparatus and methods for hematology analysis using only three detectors | |
AU2001263405B2 (en) | Flow cytometry-based hematology system | |
AU2001263405A1 (en) | Flow cytometry-based hematology system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050307 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050316 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050608 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050715 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080722 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090722 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090722 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100722 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110722 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110722 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120722 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120722 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130722 Year of fee payment: 8 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |